We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: winners18 who wrote (45931)4/28/2018 12:12:16 AM
From: dorightbythem  Respond to of 58497
First, oy. Second, 500 patients larger than expected.

To: winners18 who wrote (45931)4/28/2018 3:24:32 PM
From: erippetoe2 Recommendations

Recommended By

  Read Replies (1) | Respond to of 58497

11:25 The Promise and Challenge of T-Cell-Redirecting Bispecific Antibodies Made by the DNL? Platform

Chien-Hsing Ken Chang, PhD, Vice President, Research & Development, Immunomedics, Inc.

Accumulating evidence has indicated the antitumor immunity of T cells induced upon ligation with a bsAb to target tumor cells also incurs a concurrent activation of various cell-bound as well as -secreted factors to promote tumor growth. Elucidating the relative contribution of each of these factors to the destruction and protection of tumor presents a challenge, and provides insights into selecting optimal combination therapy with T cells redirected by bsAbs.